Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01490346 · ClinicalTrials.gov registry record
Tissue Drug Levels of HIV Medications
A clinical trial, sponsored by University of Minnesota.
- Completed
- Registry status
- 22
- Enrollment target
NCT01490346: Completed study, sponsored by University of Minnesota.
NCT01490346 is a clinical trial that has completed, run by University of Minnesota. The registered enrollment target is 22 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01490346 has completed, sponsored by University of Minnesota.
- COMPLETED
- Registry status
- 22 participants
- Enrollment target
Study Summary
The aim of this study is to find out why HIV continues to make copies in people taking HIV drugs. The investigators want to know if the medications most people use to treat HIV get into the lymphatic tissue where HIV persists.
Interventions
- DRUG Initiation of anti-retroviral therapy
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 22 participants |
| Start Date | 2008-09 |
| Est. Completion | 2014-09 |
What the finished NCT01490346 record still lists
NCT01490346 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 22 participants, a relatively small participant target.
The record links to 0 conditions, and to 1 intervention - of which Initiation of anti-retroviral therapy is the first listed.
NCT01490346 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT01490346 about?
NCT01490346 is a clinical study titled "Tissue Drug Levels of HIV Medications". The aim of this study is to find out why HIV continues to make copies in people taking HIV drugs. The investigators want to know if the medications most people use to treat HIV get into the lymphatic tissue where HIV persists.
What is the current status of trial NCT01490346?
This trial is currently completed. The enrollment target is 22 participants. The study started on 2008-09. Estimated completion is 2014-09.
What interventions are being tested in trial NCT01490346?
The interventions under investigation include: Initiation of anti-retroviral therapy (DRUG).
Who is sponsoring clinical trial NCT01490346?
This trial is sponsored by University of Minnesota, which has 966 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02508038 · 22 participants · Phase 1
Alpha/Beta CD19+ Depleted Haploidentical Transplantation + Zometa for Pediatric Hematologic Malignancies and Solid Tumors
- NCT03099356 · 22 participants · Phase 2
Cyclophosphamide and Sirolimus for the Treatment of Metastatic, RAI-refractory, Differentiated Thyroid Cancer
- NCT03676647 · 22 participants
Diagnostic DNA Methylation Signature in Diagnosing Thyroid Cancer After Fine-Needle Aspiration in Patients With Thyroid Nodules
- NCT04569591 · 22 participants · NA
DDAVP for Pituitary Adenoma
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia